logo-loader
viewValeo Pharma Inc.

Valeo Pharma begins commercialization of Yondelis, a treatment for soft tissue sarcoma

Valeo Pharma (CSE: VPH) President and CEO Steve Saviuk joined Steve Darling from Proactive with news the company has commenced commercializing Yondelis® in Canada. That product is recognized global standard of care in the treatment of soft tissue sarcoma.

Saviuk talks about when that product will be available and also about some of the other products they company plans to move forward this year.

Quick facts: Valeo Pharma Inc.

Price: 1.43 CAD

CSE:VPH
Market: CSE
Market Cap: $83.04 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics remain optimistic about US commercialisation of Accrufer...

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update. Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year. He...

2 days, 9 hours ago

2 min read